MX2010000981A - Anticuerpos para cd200 y usos de los mismos para inhibir respuestas inmune. - Google Patents

Anticuerpos para cd200 y usos de los mismos para inhibir respuestas inmune.

Info

Publication number
MX2010000981A
MX2010000981A MX2010000981A MX2010000981A MX2010000981A MX 2010000981 A MX2010000981 A MX 2010000981A MX 2010000981 A MX2010000981 A MX 2010000981A MX 2010000981 A MX2010000981 A MX 2010000981A MX 2010000981 A MX2010000981 A MX 2010000981A
Authority
MX
Mexico
Prior art keywords
inhibiting
immune responses
antibodies
inhibiting immune
cd200r
Prior art date
Application number
MX2010000981A
Other languages
English (en)
Inventor
Russell P Rother
Susan Faas Mcknight
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of MX2010000981A publication Critical patent/MX2010000981A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Esta descripción proporciona métodos y composiciones para inhibir respuestas inmunes inhibiendo la interacción entre CD200 y CD200R. La descripción también proporciona métodos y composiciones para inhibir rechazo de injerto y promover o prolongar la supervivencia de injerto inhibiendo la interacción entre C0200 y CD 200 R.
MX2010000981A 2007-07-25 2008-07-25 Anticuerpos para cd200 y usos de los mismos para inhibir respuestas inmune. MX2010000981A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96202207P 2007-07-25 2007-07-25
PCT/US2008/009037 WO2009014745A1 (en) 2007-07-25 2008-07-25 Antibodies to cd200 and uses thereof in inhibiting immune responses

Publications (1)

Publication Number Publication Date
MX2010000981A true MX2010000981A (es) 2010-05-21

Family

ID=40001380

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010000981A MX2010000981A (es) 2007-07-25 2008-07-25 Anticuerpos para cd200 y usos de los mismos para inhibir respuestas inmune.

Country Status (9)

Country Link
US (3) US8252285B2 (es)
EP (1) EP2178561A1 (es)
JP (4) JP2010534243A (es)
KR (1) KR20100041849A (es)
AU (1) AU2008279619B2 (es)
BR (1) BRPI0814644A2 (es)
CA (1) CA2697159C (es)
MX (1) MX2010000981A (es)
WO (1) WO2009014745A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2178561A1 (en) * 2007-07-25 2010-04-28 Alexion Pharmaceuticals, Inc. Antibodies to cd200 and uses thereof in inhibiting immune responses
CN102918062A (zh) 2010-02-11 2013-02-06 阿雷克森制药公司 使用抗cd200抗体的治疗方法
CA2826453A1 (en) * 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Use of an anti-cd200 antibody for prolonging the survival of allografts
DK3006464T3 (en) 2011-06-10 2018-09-17 Canada Minister Nat Defence ANTIRICIN ANTIBODIES AND APPLICATIONS THEREOF
ES2758884T3 (es) 2011-06-24 2020-05-06 Stephen D Gillies Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas
US9737598B2 (en) 2014-06-30 2017-08-22 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
CA2969384A1 (en) * 2014-12-17 2016-06-23 Cellectis Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain
AU2016349897B2 (en) 2015-11-03 2021-11-04 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
CA3026477A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
WO2018102594A1 (en) * 2016-12-01 2018-06-07 Alexion Pharmaceuticals, Inc. Methods of treating solid tumors with anti-cd200 antibodies
KR101968246B1 (ko) * 2017-04-27 2019-04-11 서울대학교산학협력단 이종 각막 이식에서 항 cd20 단일클론항체 및 타클로리무스의 복합면역억제 방법
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy
US20210087267A1 (en) 2017-12-20 2021-03-25 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
EP4296280A1 (en) 2022-06-21 2023-12-27 F. Hoffmann-La Roche AG Cd123 and cd200 as markers for the diagnosis and immune-eradication of leukemic stem cells (lscs)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1032662T3 (da) * 1997-11-07 2006-07-03 Trillium Therapeutics Inc Fremgangsmåder og sammensætninger til immunmodulation
US7223729B2 (en) * 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
EP1585545A4 (en) 2002-12-27 2006-04-12 Schering Corp PROCESS FOR INDUCING AND MAINTAINING IMMUNE COMPATIBILITY
TW200804422A (en) * 2006-01-12 2008-01-16 Alexion Pharma Inc Antibodies to OX-2/CD200 and uses thereof
EP2178561A1 (en) * 2007-07-25 2010-04-28 Alexion Pharmaceuticals, Inc. Antibodies to cd200 and uses thereof in inhibiting immune responses
BRPI0814645A2 (pt) 2007-07-25 2015-01-27 Alexion Pharma Inc Métodos e composições para tratar de doença autoimune.

Also Published As

Publication number Publication date
AU2008279619B2 (en) 2013-11-14
BRPI0814644A2 (pt) 2015-01-27
JP2015172090A (ja) 2015-10-01
JP2016117762A (ja) 2016-06-30
US8252285B2 (en) 2012-08-28
JP2010534243A (ja) 2010-11-04
US20100291085A1 (en) 2010-11-18
WO2009014745A1 (en) 2009-01-29
JP2013163695A (ja) 2013-08-22
EP2178561A1 (en) 2010-04-28
AU2008279619A1 (en) 2009-01-29
CA2697159A1 (en) 2009-01-29
US20120321625A1 (en) 2012-12-20
CA2697159C (en) 2017-02-14
USRE46323E1 (en) 2017-02-28
KR20100041849A (ko) 2010-04-22
US8637014B2 (en) 2014-01-28
JP5926702B2 (ja) 2016-05-25

Similar Documents

Publication Publication Date Title
MX2010000981A (es) Anticuerpos para cd200 y usos de los mismos para inhibir respuestas inmune.
HUS1800021I1 (hu) Humán anti-Il-23 ellenanyagok, készítmények, eljárások és alkalmazások
GB0515353D0 (en) Food
MY161909A (en) Anti-her3 antibodies and uses thereof
PH12013502230A1 (en) Multispecific antibodies
TN2010000213A1 (en) Wise binding antibodies and epitopes
TW200732349A (en) Anti-OX40L antibodies and methods using same
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
MY159679A (en) Antibodies binding preferentially human csf1r extracellular domain 4 and their use
MY160736A (en) Bivalent, bispecific antibodies
EP2244729A4 (en) ANTIBODIES OBTAINED BY CYSTEINE FOR THE SPECIFIC CONJUGATION OF A SITE
RS55888B1 (sr) Tweak vezujuća antitela
MX2010005682A (es) Anticuerpos bivalentes, biespecificos.
MX2010005888A (es) Anticuerpos bivalentes biespecificos.
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
MY154956A (en) Chimeric adenoviral vectors
MX2009003774A (es) Anticuerpos para linfotoxina-alfa.
MX2009006879A (es) Anticuerpos contra el cd200r.
MY173526A (en) Novel anti-?5?1 antibodies and uses thereof
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
MX2010000979A (es) Metodos y composiciones para tratar enfermedad autoinmune.
MX2007013108A (es) Reactivos que enlazan ccx-ckr2.
UA99332C2 (en) Herbicidal combinations having diflufenican and pinoxaden and use thereof
MX2009012643A (es) Particulas de alumina y metodos para fabricar las mismas.

Legal Events

Date Code Title Description
FG Grant or registration